Details

Autor(en) / Beteiligte

• Yoshioka, Yasuo, MD
• Kotsuma, Tadayuki, MD
• Komiya, Akira, MD
• Kariya, Shinji, MD
• Konishi, Koji, MD
• Nonomura, Norio, MD
• Ogawa, Kazuhiko, MD
• Tanaka, Eiichi, MD
• Nishimura, Kensaku, MD
• Fujiuchi, Yasuyoshi, MD
• Kitamura, Hiroshi, MD
• Yamagami, Takuji, MD
• Yamasaki, Ichiro, MD
• Nishimura, Kazuo, MD
• Teshima, Teruki, MD
• Nakamura, Katsumasa, MD
• Itami, Jun, MD

Titel

Nationwide multicenter retrospective study on high-dose-rate brachytherapy as monotherapy for prostate cancer

Ist Teil von

• International journal of radiation oncology, biology, physics, 2017-04, Vol.97 (5), p.952-961

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2017

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Purpose To present, analyze and discuss results of a nationwide multicenter retrospective study on high-dose-rate brachytherapy (HDR-BT) as monotherapy for low-, intermediate- and high-risk prostate cancer. Methods and materials From 1995 through 2013, 524 patients, 73 (14%) with low-risk, 207 (40%) with intermediate-risk, and 244 (47%) with high-risk prostate cancer, were treated with HDR-BT as monotherapy at 5 institutions in XXXXX. Dose fractionations were 27 Gy/2 fractions for 69 patients (13%), 45.5 Gy/7 fractions for 168 (32%), 49 Gy/7 fractions for 149 (28%), 54 Gy/9 fractions for 130 (25%), and others for 8 (2%). Of these patients, 156 (30%) did not receive androgen deprivation therapy (ADT), 202 patients (39%) did receive ADT <1 year, 112 (21%) for 1-3 years, and 54 (10%) for >3 years. Median follow-up time was 5.9 years (range, 0.4-18.1 years), with a minimum of 2 years for surviving patients. Results After 5 years, respective actuarial rates of no biochemical evidence of disease (bNED), overall survival (OS), cause-specific survival (CSS), and metastasis-free survival (MFS) for all patients were 92%, 97%, 99%, and 94%. For low/intermediate/high-risk patients, the 5-year bNED rates were 95%/94%/89%, the 5-year OS rates were 98%/98%/94%, the 5-year CSS rates were 98%/100%/98%, and the 5-year MFS rates were 98%/95%/90%, respectively. The cumulative incidence of late Grade 2-3 genitourinary toxicity at 5 years was 19%, and that of late Grade 3 was 1%. The corresponding incidences of gastrointestinal toxicity were 3% and 0% (0.2%). No Grade 4 or 5 of either type of toxicity was detected. Conclusions The findings of this nationwide multicenter retrospective study demonstrate that HDR-BT as monotherapy was safe and effective for all patients with low-, intermediate- and high-risk prostate cancer.